Open AccessCeftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales
Author(s) -
Weili Wang,
Rongrong Wang,
Yuntao Zhang,
Lei Zeng,
Haishen Kong,
Xueli Bai,
Wei Zhang,
Tingbo Liang
Publication year - 2022
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s369368
Subject(s) - medicine , tigecycline , ceftazidime/avibactam , interquartile range , liver transplantation , salvage therapy , avibactam , colistin , transplantation , ceftazidime , adverse effect , carbapenem , surgery , antibiotics , pseudomonas aeruginosa , chemotherapy , microbiology and biotechnology , biology , genetics , bacteria
There are few therapeutic options for infections caused by carbapenem-resistant Enterobacterales (CRE) in children following liver transplantation. Ceftazidime-avibactam (CAZ-AVI), a recently licensed antibacterial in China, was utilized as a salvage therapy against CRE in our center, and its efficacy and safety were therefore assessed.